Edition:
United Kingdom

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

11.50USD
20 Jul 2018
Change (% chg)

$0.05 (+0.44%)
Prev Close
$11.45
Open
$11.45
Day's High
$11.50
Day's Low
$11.45
Volume
79,574
Avg. Vol
25,124
52-wk High
$13.10
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Juniper Pharma To Pay Catalent Termination Fee Of $5.58 Mln Under Certain Circumstances
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Catalent Inc ::JUNIPER PHARMACEUTICALS SAYS UPON TERMINATION OF MERGER UNDER CERTAIN CIRCUMSTANCES, CO TO PAY CATALENT TERMINATION FEE OF $5.580 MILLION - SEC FILING.  Full Article

Juniper Pharmaceuticals Says Signs Definitive Agreement To Be Acquired By Catalent For $11.50 Per Share In Cash
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENT TO BE ACQUIRED BY CATALENT, INC. FOR $11.50 PER SHARE IN CASH.JUNIPER PHARMACEUTICALS - DEFINITIVE AGREEMENT WITH CATALENT FOR CATALENT TO BUY ALL OF OUTSTANDING SHARES OF CO AT $11.50 PER SHARE IN CASH.TRANSACTION REPRESENTS A TOTAL EQUITY VALUE OF APPROXIMATELY $139.6 MILLION ON A FULLY-DILUTED BASIS.TRANSACTION APPROVED UNANIMOUSLY BY JUNIPER BOARD OF DIRECTORS.ROTHSCHILD & CO IS ACTING AS FINANCIAL ADVISOR AND GOODWIN PROCTER LLP IS ACTING AS LEGAL COUNSEL TO JUNIPER.  Full Article

Catalent Signs Agreement To Acquire Juniper Pharmaceuticals
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Catalent Inc ::CATALENT SIGNS AGREEMENT TO ACQUIRE JUNIPER PHARMACEUTICALS, INC..CATALENT INC -UNDER ACQUISITION AGREEMENT WITH JUNIPER, CO'S SUBSIDIARY TO COMMENCE TENDER OFFER TO PURCHASE ALL OF JUNIPER'S SHARES FOR PRICE OF $11.50.CATALENT INC SAYS CATALENT WILL CONTINUE TO SUPPORT JUNIPER'S CRINONE FRANCHISE MARKETED BY MERCK KGAA OUTSIDE OF U.S..CATALENT INC-AFTER TENDER OFFER, CO INTENDS TO COMPLETE DEAL BY BUYING REMAINDER JUNIPER SHARES AT SAME PRICE THROUGH MERGER WITH NEWLY FORMED UNIT OF CO.  Full Article

Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06
Thursday, 10 May 2018 

May 10 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q1 EARNINGS PER SHARE $0.06.Q1 REVENUE $15.5 MILLION.JUNIPER PHARMACEUTICALS - "ENGAGEMENT WITH ROTHSCHILD TO PURSUE STRATEGIC ALTERNATIVES IS PROGRESSING".  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

Juniper Pharmaceuticals reports third quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Juniper Pharmaceuticals Inc :Juniper Pharmaceuticals reports third quarter 2017 financial and operating results.Q3 loss per share $0.13.Q3 revenue rose 12 percent to $13 million.  Full Article

Juniper Pharmaceuticals Q2 loss per share $0.16
Thursday, 4 Aug 2016 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals reports second quarter 2016 financial results . Q2 revenue $11.9 million . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue view $9.5 million -- Thomson Reuters I/B/E/S . Anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 result .Now anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 results.  Full Article

Deals of the day-Mergers and acquisitions

July 3 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: